Cytidine 5′-triphosphate disodium salt | CAS:36051-68-0

We serve Cytidine 5′-triphosphate disodium salt CAS:36051-68-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Cytidine 5'-triphosphate disodium salt

Chemical Name:Cytidine 5'-triphosphate disodium salt
CAS.NO:36051-68-0
Synonyms:Cytidine 5'-triphosphate disodium salt
cytidine tetrahydrogen triphosphate
Cytidine-5'-(tetrahydrogentriphosphate)
5'-CTP
CTP
 
Physical and Chemical Properties:
Density 2.5g/cm3
Boiling Point 849.2ºC at 760 mmHg
Molecular Formula C9H14N3Na2O14P3
Molecular Weight 527.120
Flash Point 467.4ºC
Exact Mass 526.948425
PSA 305.51000
Storage condition −20°C
 
Description:
Appearance:White to off-white powder
Assay:≥95.0%
 
Packing:5kg/bag, can also be packaged according to customer requirements
Storage:Keep dry and away from light, sealed storage in -20°C
Use:This product belongs to the nucleotide products,and can be used as biochemical reagent and intermediate for the production nucleotide drugs.And it can be used for the production of PolyI、PolyI:C.



Contact us for information like Nicotinamide riboside chloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,CTP physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Ribonucleic acid Use and application,Cytidine-5′-(tetrahydrogentriphosphate) technical grade,usp/ep/jp grade.


Related News: At the same time, because the profits of a single variety of characteristic APIs do not have long-term growth, companies need more product reserves.2,5-dichloroaniline manufacturer Professionally produce and submit DMF files, and supplement data at any time during the patent challenge of formulation companies.2,3-Difluorobenzotrifluoride supplier Professionally produce and submit DMF files, and supplement data at any time during the patent challenge of formulation companies.butyl 2-[(2Z)-2-[2-oxo-3-[(2-oxo-1,3-dihydrobenzimidazol-5-yl)carbamoyl]naphthalen-1-ylidene]hydrazinyl]benzoate vendor Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications.The US National Institutes of Health is working on a preventative vaccine, but it will likely take a few months until the first phase of clinical trials get underway, and more than a year until a vaccine might be available, according to experts.